Cargando…
Acute worsening of dermatomyositis after initiation of PARP inhibitor therapy in two women with advanced ovarian malignancy
• Chemotherapy initiation and subsequent tumor lysis can release immunogenic antigens. • Advanced staged ovarian cancer associated with dermatomyositis. • PARP Inhibitor initiation can worsen paraneoplastic syndromes like dermatomyositis. • Signs and symptoms of dermatomyositis can be confused with...
Autores principales: | Graves, Stephen M., Backes, Floor J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651899/ https://www.ncbi.nlm.nih.gov/pubmed/34926755 http://dx.doi.org/10.1016/j.gore.2021.100872 |
Ejemplares similares
-
Baseline risk of hematologic malignancy at initiation of frontline PARP inhibitor maintenance for BRCA1/2-associated ovarian cancer
por: Navitski, Anastasia, et al.
Publicado: (2021) -
Dermatomyositis recalcitrant to treatment associated with occult malignancy
por: Kane, Jennifer, et al.
Publicado: (2019) -
Rucaparib for PARP inhibitor-pretreated ovarian cancer: A GEICO retrospective subgroup analysis from the Spanish Rucaparib Access Program
por: Yubero, Alfonso, et al.
Publicado: (2023) -
Pyridoxine for prevention and treatment of PARP inhibitor induced nausea and vomiting
por: Ostby, Stuart A., et al.
Publicado: (2019) -
Erythromelalgia associated with dermatomyositis: A case series
por: Grinnell, Madison, et al.
Publicado: (2021)